Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00573391 · ClinicalTrials.gov registry record · Phase 3
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
A Phase 3 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT00573391: Clinical Trial Phase 3 study, sponsored by University of Arkansas.
NCT00573391 is a Phase 3 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 5 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00573391, a Phase 3 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).
Primary Outcome
due to low accrual rates, no analyses was done to compare the new combination of Velcade/Melphalan/Dexamethasone vs. Velcade/Thalidomide/Dexamethasone
Interventions
- DRUG Velcade, Thalidomide, and Dexamethasone
- DRUG Velcade, Melphalan, and Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Why NCT00573391 stopped before completion
NCT00573391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Velcade, Thalidomide, and Dexamethasone is the first listed.
NCT00573391 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00573391 about?
NCT00573391 is a clinical study titled "Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2". This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).
What is the current status of trial NCT00573391?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2006-08. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00573391?
The interventions under investigation include: Velcade, Thalidomide, and Dexamethasone (DRUG), Velcade, Melphalan, and Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00573391?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00573391's enrollment target sits among peer trials
5 1997th of 2000 higher than 3 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia